Exploring the relationship between specific antibodies and nasopharyngeal carcinoma linked to EBV
A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC
This study is trying to see if certain antibodies related to the Epstein-Barr virus can help in creating a vaccine to prevent nasopharyngeal carcinoma in patients who have been diagnosed with this cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05949749 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the connection between gp42-IgG antibodies and nasopharyngeal carcinoma (NPC) associated with Epstein-Barr virus (EBV) infection. By analyzing the dominant epitopes of gp42, one of the glycoproteins involved in EBV entry, the study aims to inform the design of a prophylactic vaccine against NPC. The research focuses on patients diagnosed with NPC at various stages and utilizes humanized antibodies to explore potential vaccine targets. The findings could provide insights into effective prevention strategies for this cancer type.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with nasopharyngeal carcinoma at stages I-IVB with a Karnofsky score of 70 or higher.
Not a fit: Patients with a history of other malignancies or severe systemic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of a preventive vaccine for nasopharyngeal carcinoma.
How similar studies have performed: While there is ongoing research into EBV and NPC, this specific approach utilizing gp42-IgG antibodies is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Controls underwent physical examinations or primary NPC cases confirmed by pathology or cytology. * If cases, at stage I-IVB diagnosed by radiology according to AJCC/UICC 8th. * If cases, Karnofsky score (KFS)≥70, estimated survival span\>12 months. * If cases, no disordered of major organs is found; blood test, liver, and kidney functions are basically normal. * If cases, at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. Exclusion Criteria: * History of other malignant diseases. * History of severe systemic diseases or heart, lung, liver, or kidney disfunction. * History of severe neurological, metal, endocrine diseases. * History of HBV, HCV, HIV, TP, or TB infection. * If controls, physical examination reveals systemic diseases including malignant diseases. * If cases, incomplete blood and pathological sample data. * If cases, not receiving primary treatment in this facility. * Other individuals investigators find not suitable for the trial.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen Memorial Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Xiao-Ming Huang, M.D. — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Study coordinator: Xiang-Wei Kong, Ph.D.
- Email: sorahick@qq.com
- Phone: 0086-020-34071439
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.